Careers of Young Survivors Can be Disrupted by Late-Emerging Side Effects of Cancer Treatment

Article

Side effects that arise months or years after adolescents and young adults (AYAs) have completed cancer treatment — known as late effects — can significantly affect both careers and quality of life in this population.

Side effects that arise months or years after adolescents and young adults (AYAs) have completed cancer treatment — known as late effects — can significantly affect both careers and quality of life in this population, according to two studies presented at the 2017 European Society for Medical Oncology Congress in Madrid, Spain, on Sept. 9.

The NOR-CAYAS study examined the work capacity of patients who had been diagnosed between the ages of 19 and 39. The study followed 1,198 patients after their treatment for melanoma, colorectal cancer, breast cancer, non-Hodgkin lymphoma or leukemia. The median age of participants at the time of the survey was 49, and the median amount of years since treatment was 13.

Sixty percent of survivors questioned held a full-time job. Authors found that those less likely to have full-time jobs were women with a low level of education, lymphedema, fatigue, depression and/or reduced physical quality of life or self-reported health.

“We found that psychological and physical late effects of cancer and other conditions were significantly associated with reduced work ability,” said lead author Cecilie Kiserud, M.D., Ph.D., chair of the National Advisory Unit for Late Effects After Cancer Treatment at Oslo University Hospital, in Oslo, Norway. “In comparison, treatment intensity and cancer type, apart from non-Hodgkin lymphoma, were not significantly related to work ability.”

Kiserud went on to emphasize that more awareness is needed regarding the fact that people in this population may be less able to work after cancer treatment due to late effects.

But the late effects of cancer treatment did not only affect AYA survivors in the workplace.

Another study presented at ESMO found that, in Europe, 67 percent of 266 health care professionals who were treating AYA patients did not have access to a center specializing in the needs of people in this age group to manage their late effects. Further, 69 percent reported that they were not aware of any research being conducted in their countries that focused on the AYA population.

Thirty-eight percent of health care professionals surveyed said that their patients did not have access to fertility specialists, and within Eastern Europe, that number jumped to 76 percent.

One important aspect to note, though, was that most of the physicians involved were able to refer their AYA patients for psychosocial support.

“These patients have specific needs that are not covered by pediatric or general oncology centers or classical medical oncology centers, and this survey shows that most do not have access to the recommended special care. Countries without these services can look at existing examples — such as in the U.K. and France — to build teams equipped to improve survival and survivorship for adolescents and young adults with cancer,” said lead author Emmanouil Saloustros, M.D., a consultant medical oncologist at the General Hospital of Heraklion “Venizelio,” in Heraklion, Crete, Greece.

Related Videos
For patients with cancer, the ongoing chemotherapy shortage may cause some anxiety as they wonder how they will receive their drugs. However, measuring drugs “down to the minutiae of the milligrams” helped patients receive the drugs they needed, said Alison Tray. Tray is an advanced oncology certified nurse practitioner and current vice president of ambulatory operations at Rutgers Cancer Institute in New Jersey.  If patients are concerned about getting their cancer drugs, Tray noted that having “an open conversation” between patients and providers is key.  “As a provider and a nurse myself, having that conversation, that reassurance and sharing the information is a two-way conversation,” she said. “So just knowing that we're taking care of you, we're going to make sure that you receive the care that you need is the key takeaway.” In June 2023, many patients were unable to receive certain chemotherapy drugs, such as carboplatin and cisplatin because of an ongoing shortage. By October 2023, experts saw an improvement, although the “ongoing crisis” remained.  READ MORE: Patients With Lung Cancer Face Unmet Needs During Drug Shortages “We’re really proud of the work that we could do and achieve that through a critical drug shortage,” Tray said. “None of our patients missed a dose of chemotherapy and we were able to provide that for them.” Tray sat down with CURE® during the 49th Annual Oncology Nursing Society Annual Congress to discuss the ongoing chemo shortage and how patients and care teams approached these challenges. Transcript: Particularly at Hartford HealthCare, when we established this infrastructure, our goal was to make sure that every patient would get the treatment that they need and require, utilizing the data that we have from ASCO guidelines to ensure that we're getting the optimal high-quality standard of care in a timely fashion that we didn't have to delay therapies. So, we were able to do that by going down to the minutiae of the milligrams on hand, particularly when we had a lot of critical drug shortages. So it was really creating that process to really ensure that every patient would get the treatment that they needed. For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.
Yuliya P.L Linhares, MD, an expert on CLL
Yuliya P.L Linhares, MD, and Josie Montegaard, MSN, AGPCNP-BC, experts on CLL
Image of a man with a beard.
Image of a man with gray facial hair and a navy blue suit with a light orange tie.
Image of a woman with black hair.
Related Content